Welcome to our dedicated page for Livanova news (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on Livanova stock.
LivaNova PLC reports developments as a global medical technology company focused on selected neurological and cardiac conditions. Company news commonly covers revenue results and guidance, performance in its Cardiopulmonary and Epilepsy businesses, and updates tied to medical-device commercialization and clinical evidence.
Recurring product themes include VNS Therapy for drug-resistant epilepsy, real-world evidence from the CORE-VNS study, and obstructive sleep apnea technology using proximal hypoglossal nerve stimulation. Updates also include FDA regulatory decisions, including premarket approval for the aura6000 System, investor conference appearances, and business update calls.
LivaNova PLC (NASDAQ:LIVN) will host a conference call on October 29, 2020, at 12 p.m. London time to discuss its third-quarter 2020 results, releasing the results prior to the call. The audiocast will be available in the Investor Relations section of LivaNova's website, with listeners advised to log on 10 minutes early. For telephone participation, dial 844-239-5285 (U.S.) or 512-961-6524 (international), using conference ID 1897870. A replay will be accessible for 90 days post-call. LivaNova operates in Cardiovascular and Neuromodulation sectors, serving over 100 countries.